鼻咽癌患者血清MTA1浓度与临床特征及预后的关系

目的:本研究旨在检测鼻咽癌患者治疗前血清中MTA1的水平，探讨其与临床特征及预后的关系。方法:收集2011年3月至2015年4月在我院治疗的初诊无转移鼻咽癌患者96例的临床资料及治疗前血清标本。利用ELISA方法测定血清MTA1浓度，以中位浓度为截断值，将患者分为低表达组和高表达组，采用单因素和多因素方法分析治疗前患者血清中MTA1浓度与临床病理特征及生存率的关系。结果:全组患者血清MTA1中位浓度为112 pg/ml（0~8 215 pg/ml），中位随访47个月，23例患者发生远处转移，治疗前MTA1水平与远处转移相关（P=0.031），但与性别、年龄、T、N分期及临床分期均无关。生存率分析显示，MTA1高表达组4年DMFS为73.2%，显著低于MTA1低表达组的86.7%（P=0.039）；MTA1高表达组与低表达组患者4年PFS分别为 70.8%和87.3%，趋向于有统计学意义（P=0.054）；尽管MTA1高表达患者4年OS低于MTA1低表达患者，但差异无显著统计学意义（82.1% vs 86.9%,P=0.091）。多因素分析表明:治疗前患者血清MTA1表达水平并不是鼻咽癌患者OS、PFS及DMFS的独立预后因素（P=0.349、P=0.126、P=0.106）。结论:鼻咽癌患者治疗前血清MTA1高表达与无转移生存相关。

Correlation of serum MTA1 concentration to clinical characteristics of nasopharyngeal carcinoma and its prognosis

Objective:To detect the level of MTA1 in the serum of patients with nasopharyngeal carcinoma and to explore its correlation with clinical characteristic and the prognosis.Methods:Pretreatment serum specimens and clinical data were collected from 96 patients who were newly diagnosed with non-metastatic NPC in our hospital from March 2011 to April 2015.The expression of serum MTA1 was detected by ELISA and classified into low or high-expression using a 50% cut-off level.The relationships of MTA1 with clinical characteristics and survival of patients were analyzed by univariate and multivariate analysis.Results:The median concentration of serum MTA1 in the whole group was 112 pg/ml（0~8 215 pg/ml).The median follow-up time was 47 months.23 patients developed distant metastasis.The level of MTA1 was related to distant metastasis（P=0.031),but there was no relation between MTA1 and gender,age,T,N stage and clinical stage.Univariate survival analysis showed that the 4-year DMFS in MTA1 high-expression group was 73.2%,which was significantly lower than that in MTA1 low-expression group 86.7%（P=0.039).The 4-year PFS in MTA1 high-expression group and MTA1 low-expression group tended to be significant difference（70.8% vs 87.3%,P=0.054).Although the 4-year OS in MTA1 high-expression group was poor than that in MTA1 low-expression group,there was no significance（82.1% vs 86.9%,P=0.091).Furthermore,multivariate analysis revealed that pretreatment serum MTA1 expression was not an independent prognostic factor for DMFS,PFS and OS of NPC patients（P=0.106,P=0.126,P=0.349).Conclusion:The high expression of pretreatment serum MTA1 is related with DMFS of NPC patients.